NO965590L - Polynukleotidvaksine for papillomvirus - Google Patents

Polynukleotidvaksine for papillomvirus

Info

Publication number
NO965590L
NO965590L NO965590A NO965590A NO965590L NO 965590 L NO965590 L NO 965590L NO 965590 A NO965590 A NO 965590A NO 965590 A NO965590 A NO 965590A NO 965590 L NO965590 L NO 965590L
Authority
NO
Norway
Prior art keywords
dna
crpv
hpv
gene
papilloma virus
Prior art date
Application number
NO965590A
Other languages
English (en)
Norwegian (no)
Other versions
NO965590D0 (no
Inventor
Donna L Montgomery
John J Donnelly
Margaret A Liu
Douglas Martinez
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO965590D0 publication Critical patent/NO965590D0/no
Publication of NO965590L publication Critical patent/NO965590L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO965590A 1994-06-30 1996-12-27 Polynukleotidvaksine for papillomvirus NO965590L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (fr) 1994-06-30 1995-06-01 Vaccin polynucleotidique contre le virus du papillome

Publications (2)

Publication Number Publication Date
NO965590D0 NO965590D0 (no) 1996-12-27
NO965590L true NO965590L (no) 1997-02-28

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965590A NO965590L (no) 1994-06-30 1996-12-27 Polynukleotidvaksine for papillomvirus

Country Status (20)

Country Link
US (1) US5866553A (fr)
EP (1) EP0768893B1 (fr)
JP (1) JPH10501987A (fr)
CN (1) CN1156966A (fr)
AT (1) ATE233101T1 (fr)
AU (1) AU701973B2 (fr)
CA (1) CA2193365C (fr)
CZ (1) CZ375296A3 (fr)
DE (1) DE69529748T2 (fr)
ES (1) ES2191052T3 (fr)
FI (1) FI965224A0 (fr)
HU (1) HU220747B1 (fr)
IL (1) IL113817A (fr)
MX (1) MX9700229A (fr)
NO (1) NO965590L (fr)
NZ (1) NZ288045A (fr)
PL (1) PL180639B1 (fr)
SK (1) SK164196A3 (fr)
WO (1) WO1996000583A1 (fr)
ZA (1) ZA954641B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
ES2232934T3 (es) * 1997-02-14 2005-06-01 MERCK & CO., INC. Formulaciones de vacunas a base de polinucleotidos.
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3489499A (en) * 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
SI1108035T1 (sl) * 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
WO2000046147A2 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
ATE397942T1 (de) * 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
EP1212358B1 (fr) * 1999-08-25 2004-12-15 Merck & Co., Inc. Genes synthetiques humains du virus de papillome
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
KR20040043129A (ko) * 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
CA2586035A1 (fr) * 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium destinees a la medecine esthetique ou cosmetique, et procedes de fabrication et d'utilisation
WO2006083984A1 (fr) * 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides du papillomavirus a terminaison l2 n permettant d'induire des anticorps a neutralisation croisee large
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
US9428555B2 (en) * 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
KR20150128900A (ko) * 2013-03-15 2015-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
JP2648303B2 (ja) * 1985-04-04 1997-08-27 ジョージタウン・ユニバーシティ 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
CA2489769A1 (fr) * 1989-03-21 1990-10-04 Philip L. Felgner Expression des sequences polynocleotides exogenes chez un vertebre
ES2194839T3 (es) * 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
DK0586076T3 (da) * 1992-08-07 2003-10-20 Wyeth Corp Rekombinant adenovirus-vacciner
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
CA2193365C (fr) 2007-04-03
WO1996000583A1 (fr) 1996-01-11
ZA954641B (en) 1996-01-26
SK164196A3 (en) 1997-08-06
FI965224L (fi) 1996-12-27
HUT76446A (en) 1997-09-29
AU701973B2 (en) 1999-02-11
CA2193365A1 (fr) 1996-01-11
HU9603562D0 (en) 1997-02-28
NO965590D0 (no) 1996-12-27
IL113817A0 (en) 1995-08-31
DE69529748T2 (de) 2003-10-16
IL113817A (en) 2001-03-19
HU220747B1 (hu) 2002-05-28
US5866553A (en) 1999-02-02
PL180639B1 (pl) 2001-03-30
CN1156966A (zh) 1997-08-13
JPH10501987A (ja) 1998-02-24
ATE233101T1 (de) 2003-03-15
CZ375296A3 (en) 1997-08-13
AU2694595A (en) 1996-01-25
FI965224A7 (fi) 1996-12-27
FI965224A0 (fi) 1996-12-27
EP0768893B1 (fr) 2003-02-26
NZ288045A (en) 1998-08-26
DE69529748D1 (de) 2003-04-03
PL317874A1 (en) 1997-04-28
MX9700229A (es) 1997-04-30
EP0768893A1 (fr) 1997-04-23
ES2191052T3 (es) 2003-09-01

Similar Documents

Publication Publication Date Title
AU701973B2 (en) Polynucleotide vaccine for papillomavirus
RU2360001C2 (ru) Оптимизированная экспрессия l1 hpv45 в дрожжах
Lin et al. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product
US10736954B2 (en) L2 peptide immunogenicity
NO328128B1 (no) Antigenisk formulering som omfatter et humant papillomaviruskapsomer for anvendelse som en vaksine, samt anvendelse derav for fremstilling av en farmasoytisk sammensetning for behandling og forebygging av HPV infeksjon og tilstander beslektet dermed.
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN116284272B (zh) 一种广谱抗牛科病毒性腹泻病毒的mRNA疫苗及其应用
WO2021013071A1 (fr) Composition polyvalente induisant l'immunogénicité pour papillomavirus humain
AU708460B2 (en) A polynucleotide herpes virus vaccine
US20050118139A1 (en) Vaccine using papilloma virus e proteins delivered by viral vector
Jagu et al. A multimeric L2 vaccine for prevention of animal papillomavirus infections
CN100393878C (zh) 疫苗
CN101735310A (zh) Hpv融合蛋白、基因、载体、菌株、制备方法及用途
RU2173170C2 (ru) Полинуклеотидная вакцина для вируса папилломы
Cao et al. Expression and immunogenicity of hepatitis E virus-like particles based on recombinant truncated ORF2 capsid protein
Deng et al. The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
Kwak Development of prophylactic human papillomavirus vaccines
CZ28899A3 (cs) Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů
HK40006519A (en) Improvement of hpv l2 peptide immunogenicity
HK40006519B (en) Improvement of hpv l2 peptide immunogenicity
AU5013099A (en) Papillomavirus vaccine
NO176996B (no) Fremgangsmåte for fremstilling av en farmasöytisk sammensetning for beskyttelse av felin leukemivirus (FeLV)
AU4889102A (en) Papillomavirus vaccine
CN104558196A (zh) 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application